Extensive studies have shown that blocking the PI3K/Akt signaling pathway enhances the sensitivity of various drug-resistant human cancer cells to several drugs, including cisplatin, oxaliplatin, and gemcitabine (39–41). This evidence concerns the gene AKT1 and cancer.